M. Taal

First name
M.
Middle name
W.
Last name
Taal
Abhishek, A., Grainge, M., Card, T., Williams, H. C., Taal, M. W., Aithal, G. P., et al. (2024). Risk-stratified monitoring for sulfasalazine toxicity: prognostic model development and validation. Rmd Open, 10. http://doi.org/10.1136/rmdopen-2023-003980
Nakafero, G., Card, T., Grainge, M. J., Williams, H. C., Taal, M. W., Aithal, G. P., et al. (2023). Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation. Eclinicalmedicine, 64, 102213. http://doi.org/10.1016/j.eclinm.2023.102213
Nakafero, G., Grainge, M. J., Williams, H. C., Card, T., Taal, M. W., Aithal, G. P., et al. (2023). Risk stratified monitoring for methotrexate toxicity in immune mediated inflammatory diseases: prognostic model development and validation using primary care data from the UK. Bmj, 381, e074678. http://doi.org/10.1136/bmj-2022-074678
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Riley, R., van der Windt, D., et al. (2022). Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatol Adv Pract, 6, rkac046. http://doi.org/10.1093/rap/rkac046
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Zhang, W., Doherty, M., et al. (2021). What is the incidence of methotrexate or leflunomide discontinuation related to cytopenia, liver enzyme elevation or kidney function decline?. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keab254
Nakafero, G., Grainge, M. J., Card, T., Taal, M. W., Aithal, G. P., Zhang, W., et al. (2021). Development and validation of a prognostic model for leflunomide discontinuation with abnormal blood-tests during long-term treatment: cohort study using data from Clinical Practice Research Datalink Gold and Aurum. Rheumatology (Oxford). http://doi.org/10.1093/rheumatology/keab790